
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Services-Prepackaged Software · market cap $14.6B · as of 2026-06-25
Research and calibrated estimates, not financial advice — verify before acting.
No upcoming catalysts in our calendar.
| Asset | Phase | Indication |
|---|---|---|
| GN-037 | Phase 2 | Psoriasis |
| Lactobacillus brevis CD2 Lozenges | Phase 3 | Chronic Periodontitis |
| Probiotic | Phase 3 | Chronic Periodontitis |
| Probiotic (L. brevis CD2 lozenges) | Phase 3 | Malocclusion |
Daily closes through 2026-06-24. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.